CLINICAL_TRIALS
trial_result
· 2018-02-05
Clinical Trial Update: A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain [Phase 3]
Summary
Phase 3 study of macitentan to validate PAH-SYMPACT in France, Italy and Spain was terminated with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2018-02-05